2024 / 04

Next Paper
DOI: 10.24075/medet.2024.022
Copyright: © 2024 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Antirheumatic activity of 3-imidazole-substituted-4,5-diaryloisoxazol-3-carboxylic acid amide derivative, a proteinase inhibitor-activated type II receptor

Fedorov VN1,2, Korsakov MK1, Shetnev AA1,2, Grechischeva OV1,2, Vdovichenko VP3, Volkhin NN1,2, Smirnov NA2, Khokhlova AA4, Arshinov AV3
About authors

1 Yaroslavl State Pedagogical University named after KD Ushinsky

2 Yaroslavl State Medical University, Yaroslavl, Russia

3 Grodno State Medical University, Grodno, Belarus

4 Russian University of Medicine, Moscow, Russia

Correspondence should be addressed: Nikita N Volkhin
Technopark str., 11/2, Yaroslavl, 150030, Russia; ur.umsy@nihklovnn

About paper

Funding: this study was supported by the Ministry of Health of the Russian Federation (state assignment 1022051600008-9-3.1.5;3.2.22) “Development of a drug for the treatment of rheumatoid arthritis and other inflammatory diseases”.

Acknowledgement: the work was carried out in collaboration with the Scientific Department of the Institute of Pharmacy of Yaroslavl State Medical University, Yaroslavl.

Author contribution: Fedorov VN — idea development, analysis and layout of the collected material; Korsakov MK — writing the text; Shetnev AA — a general idea and planning of the article, synthesis of the compound under study; Grechishcheva OV — conducting an experiment; Vdovichenko VP — collection and primary analysis of material, working with literature; Volkhin NN — conducting an experiment; Smirnov NA — primary analysis of the collected material; Khokhlova AA — collection of primary material, design of the list of references; Arshinov AV — text editing.

Compliance with ethical standards: the study was carried out in compliance with all ethical standards recommended in the Russian Federation. Rats were selected as a test system, as animals with a minimum set of characteristics that make it possible to conduct an experiment: a sufficient size of paws for convenient measurements and possibility of taking the volume of blood necessary for the study. The animals were kept in cages of sufficient area and with timely bedding change (2 times a week). Animals are provided with free access to water and food, a 12-hour lighting cycle, optimal temperature and humidity, and supervision by a licensed veterinarian. Although the research protocol did not allow to use painkillers that could distort the results of experiments, all procedures were carried out by qualified and experienced personnel, which ensured minimization of stress and pain. The animal study was preceded by in vitro studies of the drug. The power of the statistical tests used was evaluated, which made it possible to form samples of an optimal size. The animal study was approved by the Independent Ethical Committee of the Federal State Budgetary Educational Institution of Higher Education Yaroslavl State Medical University of the Ministry of Health of the Russian Federation, Protocol No. 6 dated 09/14/2023.

Received: 2024-10-29 Accepted: 2024-11-15 Published online: 2024-12-13
|
  1. GBD 2021 Rheumatoid Arthritis Collaborators. Global, regional, and national burden of rheumatoid arthritis, 1990–2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. The Lancet Rheumatology. 2023; 5 (10): e594-e610. DOI: 10.1016/S2665-9913(23)00211-4. PMID: 37795020; PMCID: PMC10546867.
  2. Klinicheskie rekomendatsii. Revmatoidnyy artrit. 2021–2022–2023 (24.08.2021). Utverzhdeny Minzdravom RF. Russian.
  3. Tanaka Y. Current concepts in the management of rheumatoid arthritis. Korean J Intern Med. 2016; 31 (2): 210–218. DOI: 10.3904/kjim.2015.137. Epub 2016 Feb 26. PMID: 26932398; PMCID: PMC4773729.
  4. Nasonov EL. Lechenie revmatoidnogo artrita. Klinicheskaya farmakologiya i farmakoterapiya. 2017; 26 (1): 4–10. Russian.
  5. Prasad P, Verma S, Surbhi, Ganguly NK, Chaturvedi V, Mittal SA. Rheumatoid arthritis: advances in treatment strategies. Mol Cell Biochem. 2023; 478 (1): 69–88. DOI: 10.1007/s11010-022-04492-3. PMID: 35725992.
  6. McCulloch K, McGrath S, Huesa C, Dunning L, Litherland G, Crilly A, et al. Rheumatic Disease: Protease-Activated Receptor-2 in Synovial Joint Pathobiology. Front Endocrinol (Lausanne). 2018; 9: 257. DOI: 10.3389/fendo.2018.00257. PMID: 29875735; PMCID: PMC5974038.
  7. Cho NC, Seo SH, Kim D, Shin JS, Ju J, Seong J, et al. Pharmacophore-based virtual screening, biological evaluation and binding mode analysis of a novel protease-activated receptor 2 antagonist. J Comput Aided Mol Des. 2016; 30 (8): 625–37. DOI: 10.1007/s10822-016-9937-9. PMID: 27600555.
  8. Abassi YA, Xi B, Zhang W, Ye P, Kirstein SL, Gaylord MR, et al. Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. Chem Biol. 2009; 16 (7): 712–23. DOI: 10.1016/j.chembiol.2009.05.011. PMID: 19635408; PMCID: PMC2836189.
  9. Korsakov MK, Fedorov VN, Smirnov NA, Shetnev AA, Leonova OV, Volkhin NN, et al. Screening of anti-inflammatory activity of 4.5-dihydroisoxazol-5-carboxamide (PAR-2 inhibitors) based on formaldehyde oedema model among white lab rats. Research Results in Pharmacology. 2023; 9 (4): 105–111. DOI: 10.18413/rrpharmacology.9.10061.
  10. Tuncel J, Haag S, Hoffmann MH, Yau AC, Hultqvist M, Olofsson P, et al. Animal Models of Rheumatoid Arthritis (I): Pristane-Induced Arthritis in the Rat. PLoS One. 2016 May 26; 11 (5): e0155936. DOI: 10.1371/journal.pone.0155936. PMID: 27227821; PMCID: PMC4881957.
  11. Bibik EYu, Yaroshevskaya OG, Devdera AV, Demenko AV, Zakharov VV, Frolov KA, et al. Poisk sredstv s protivovospalitel’noy aktivnost’yu sredi proizvodnykh tetragidropirido [2,1] [1,3,5] tiadiazina. Khimiko-farmatsevticheskiy zhurnal. 2017; 51 (8): 16–19. Russian.
  12. Skupnevskiy SV, Pukhaeva EG, Badtiev AK, Rurua FK, Batagova FE, Farnieva Zh G. Metod neinvazivnoy otsenki razvitiya revmatoidnogo artrita u laboratornykh gryzunov. Vestnik novykh meditsinskikh tekhnologiy. 2022; (4): 69–72. DOI: 10.24412/1609-2163-2022-4-69-72. Russian.
  13. Glants S. Mediko-biologicheskaya statistika. M.: Praktika, 1998; 459 p. Russian.